Loading institutional data...
Loading institutional data...
Held by 222 of 5,944 reporting institutions (92th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$214M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -49%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-08-05
Where each multiple sits in its own 14-yr range · 68th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 7.3 | 2.8 | 2.7 | 2.2 | 4.2 | 4.4 | 2.8 | 12.9 |
| R&D | 696.7 | 1194.3 | 573.4 | 1146.2 | 3489.9 | 1714.5 | 2329.8 | 15862.4 |
| SG&A | 202.0 | 431.7 | 194.9 | 440.5 | 1153.8 | 449.1 | 549.1 | 2837.4 |
| Operating Income | -1640.1 | -1540.2 | -854.1 | -1531.8 | -4889.0 | -2245.3 | -2778.9 | -18599.8 |
| Income Tax | -8.0 | — | -15.7 | -4.9 | — | 0.0 | 0.0 | 0.0 |
| Net Income | — | — | — | -1516.0 | -4765.6 | -2054.8 | -2248.8 | -16748.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CLDX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M 100.0% | $7.0M 100.0% | $6.9M 100.0% | $2.4M 100.0% | $4.7M 100.0% | $7.4M 100.0% | $3.6M 100.0% | $9.5M 100.0% | $12.7M 100.0% | $6.8M 100.0% |
| Cost of Revenue | $200K 12.9% | $200K 2.8% | $300K 4.4% | $100K 4.2% | $100K 2.2% | $200K 2.7% | $100K 2.8% | $700K 7.3% | $700K 5.5% | $1.6M 23.6% |
| Research & Development | $245.1M 15862.4% | $163.6M 2329.8% | $118.0M 1714.5% | $82.3M 3489.9% | $53.3M 1146.2% | $42.5M 573.4% | $42.7M 1194.3% | $66.4M 696.7% | $96.2M 754.7% | $102.7M 1513.8% |
| Selling, General & Admin | $43.8M 2837.4% | $38.5M 549.1% | $30.9M 449.1% | $27.2M 1153.8% | $20.5M 440.5% | $14.5M 194.9% | $15.4M 431.7% | $19.3M 202.0% | $25.0M 196.2% | $36.0M 530.2% |
| Total Operating Expenses | $288.9M 18699.8% | $202.1M 2878.9% | $161.4M 2345.3% | $117.6M 4989.0% | $75.9M 1631.8% | $70.8M 954.1% | $58.6M 1640.2% | $166.0M 1740.1% | $134.3M 1053.7% | $139.7M 2058.7% |
| Operating Income | -$287.4M -18599.8% | -$195.1M -2778.9% | -$154.5M -2245.3% | -$115.2M -4889.0% | -$71.2M -1531.8% | -$63.4M -854.1% | -$55.0M -1540.2% | -$156.4M -1640.1% | -$121.5M -953.7% | -$132.9M -1958.7% |
| Pretax Income | -$258.8M -16748.0% | -$157.9M -2248.8% | -$141.4M -2054.8% | -$112.3M -4765.6% | -$70.7M -1520.9% | -$60.9M -821.6% | -$50.9M -1424.0% | -$151.9M -1593.1% | -$117.3M -920.6% | -$128.5M -1894.0% |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | — | -$227K -4.9% | -$1.2M -15.7% | — | -$765K -8.0% | -$24.3M -190.6% | — |
| Net Income | -$258.8M -16748.0% | -$157.9M -2248.8% | -$141.4M -2054.8% | -$112.3M -4765.6% | -$70.5M -1516.0% | — | — | — | — | — |
| Per Share | ||||||||||
| EPS (Basic) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 | $-3.51 | — | — | — |
| EPS (Diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 | $-3.51 | — | — | — |
| Weighted Avg Shares (Basic) | 66.4M | 64.4M | 48.4M | 47K | 43K | 30K | 15K | — | — | — |
| Weighted Avg Shares (Diluted) | 66.4M | 64.4M | 48.4M | 47K | 43K | 30K | 15K | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| CLDX | $2.7B | — | — | 1768.6× | -78.0% | 87.1% | -16748% | -49.1% | -49.1% | — | 222 |
Peers = companies sharing CLDX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.